US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application
Executive Summary
Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years.
You may also be interested in...
US Consumer Health Industry In 2023: Monograph Results, Switch Hopes On OTC Drug Sector Radar
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight reports on OTC drug sector’s outlook for the FDA potentially publishing a final rule to expand switch opportunities as well as its anticipation of marketplace results from monograph program overhaul.
'Catch-Up’ Symptoms Slow Perrigo In Cold Season
Strong cough/cold season forecast bodes well for upper respiratory and other OTCs Perrigo provides as private label and store brand products, but it isn’t expecting to capitalize in the Americas due to lingering impacts from supply chain and production disruptions linked to the COVID-19 pandemic.
Healthcare Professionals In Spain Call On Government To Switch Contraceptive Pill
Representatives of doctors and pharmacists have met with the director of the Spanish Agency for Medicines and Medical Devices to discuss a position paper which argues enabling OTC access to the daily contraceptive pill will empower women to manage their own reproductive health and improve family planning.